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interaction (respectively termed a- and 13-sites) have been Abstract We have previously shown that L58 in the putative 5th 
helical region of human interleuidn-6 (IL-6) is important for identified and are dispersed throughout the putative tertiary 
activation of the IL-6 signal transducer gpl30 Ide Hon et al. structure (reviewed in [9]). The a-site is spatially separated 
(1995) FEBS Lett. 369, 187-1911. To further explore the from the I~-sites (l~l-~a), and is comprised of residues in the 
importance of individual residues in this region for gpl30 A- and D-helix and in the loop between helices A and B. The 
activation we have now combined Ala substitutions of residues 131-site comprises residues Q153-H165 at the end of the C-D 
E52, $53, $54, K55, E56, L58 and E60 with other substitutions loop and top of helix D, the 132-site residues K42-A57 cover- 
in IL-6, known to affect gpl30 activation (QI60E and T163P). ing the loop created by the first cysteine bridge and part of the 
The combination mutant protein with L58A completely lost the putative 5th helical region in the A-B loop, and the I~a-site 
capacity to induce the proliferation of XG-I myeloma cells, and residues Y32, G36, S119 and V122, located in the A- and C- 
could effectively antagonize wild type IL-6 activity on these cells, helix [8,10]. The a- and 133-site of IL-6 correspond to binding 
Moreover, the data suggest hat besides L58, $54 particularly, 
but also E52, $53, K55 and E56 contribute to gpl30 activation, sites 1 and 2 of human growth hormone respectively [10,11]. 
In the hexameric IL-6-receptor complex, regions 131 and 132 are 
Key words: lnterleukin-6; Structure-function a alysis; gpl30 thought o form a composite binding site for one gpl30 mol- 
ecule, whereas 13z is thought to contact the second gpl30 
[4,12]. Single I~1- but not 132-site mutant proteins are partial 
IL-6 receptor antagonists: they antagonized IL-6 activity on 
1. Introduction the human IL-6 responsive cell lines CESS and HepG2, but 
not on XG-1 and TF-1 cells [5,13-15]. When 131 and 132 sub- 
Interleukin-6 is a pleiotropic cytokine which, in concert stitutions are combined however, a synergistic loss of activity 
with other cytokines like IL-113 and TNFa, regulates the is observed: the resulting combination mutants are completely 
host defense reactions in response to infections, trauma or inactive and antagonize 1L-6 activity on the XG-1 and TF-1 
neoplastic growth [1,2]. IL-6 functions through binding to a cells as well [14,16]. This antagonistic activity can further be 
type I cell surface transmembrane receptor composed of two improved by introducing two mutations (F171L/S177R, ab- 
different chains. A specific 80 kDa a-chain is responsible for breviated 'LR') that enhance the affinity of IL-6 for IL-6Ra 
low affinity binding of IL-6, whereas the complex of ligand [14,16]. Similarly, simultaneous substitution of all [33 residues 
and a-chain subsequently associates with a second non-spe- results in an IL-6RA on a variety of human cell lines [10]. 
cific signal transducing ([3) chain, gpl30 [2]. The end result of Recently we performed alanine scanning mutagenesis of a 
IL-6 receptor binding is thought o be a hexameric omplex number of residues in the putative 5th helical region of IL-6 
that signals into the cell, composed of dimers of the ligand (around the 132-site), including residues E52, $53, $54, K55, 
and each receptor chain [3,4]. E56, L58 and E60, to identify single amino acids important 
Human IL-6 has been implicated in the pathogenesis of a for gpl30 interaction [17]. In that study only the L58A sub- 
wide variety of human diseases [1]. IL-6 antagonists may stitution resulted in an IL-6 mutant protein with 5-fold re- 
therefore have clinical applications. With the aim to develop duced biological activity and gpl30 binding [17]. These data 
such molecules, we study the structure-function relationships were in apparent contradiction with those of Ehlers et al. who 
of human IL-6. Based on homology with granulocyte-colony showed that simultaneous substitution of residues C51-E56 
stimulating factor, the crystal structure of which has been with the corresponding residues of mouse IL-6 (mutant 2a2) 
determined, a tertiary structure model of IL-6 has been built resulted in a 30-fold reduced biological activity and a similar 
[5]. In this model, IL-6 has the characteristic core structure of reduction in gpl30 binding [16]. Together these data could 
the long-chain family of cytokines [6,7], consisting of a bundle suggest hat residues 51-56 have a minor contribution in 
of 4 a-helices (named A-D), connected with long loops [5,8]. gpl30 binding, which could only be detected by simultaneous, 
Various regions of IL-6 that are important for a- or 13-chain but not by single substitution of these residues. Because of the 
strong synergy between 131 and 1~2 substitutions [14,16], we 
reasoned that another way to detect a contribution of the *Corresponding author. Fax: (31) (20) 5123170. 
single residues in this region to biological activity and gpl30 
Abbreviations: wtlL-6, wild type interleukin-6 binding, might be to combine them with ~1 substitutions 
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[14,16]. In addition, this study was undertaken to determine was measured to compete for binding of biotinylated wtlL-6 to im- 
the min imum number of substitutions required in the 152 re- mobilized soluble (s) human IL-6R~, as described [14,15]. 
gion, to generate an IL-6 receptor antagonist. Combinat ion 2.6. ELISA protocols 
mutants of the single Ala substitution mutants with IL- The reactivity of the IL-6 mutant proteins with conformation spe- 
6.Q160E/T163P/F171L/S177R (IL-6.[~I/LR) were therefore cific monoclonal antibodies (mAbs) CLB.IL-6/8, CLB.IL-6/12 and 
constructed and tested for biological activity and receptor CLB.IL-6/14 was measured in sandwich ELISAs with the mAbs as 
coating antibody, serial dilutions of the mutant protein preparations 
binding characteristics, and affinity purified biotinylated sheep polyclonal anti-rhlL-6 as de- 
tecting antibodies as described [19]. mAb 8 and 12 are neutralizing 
2. Materials and methods mAbs. mAb 8 recognizes the carboxyl-terminus of IL-6 and mAb 12 
recognizes the amino-terminus around residue 125. mAb 14 is a non- 
2.1. Cytokines neutralizing mAb, with an epitope that partially overlaps with that of 
The wild type (wt)IL-6 preparation used as a standard was mature mAb 8 [19]. 
recombinant human (rh) IL-6 (A1-M185) purified from E. coli BL21 
(DE3) carrying the pET8c-hlL-6 cDNA expression vector [13]. E. coli 3. Results and dlseussion 
derived human oncostatin M (rhOM) was from Preprotech (Rocky- 
hill, USA), human granulocyte macrophage-colony stimulating factor 
(hGM-CSF) was from Sandoz, Basel, Switzerland. 3.1. Synergistic loss of IL-6 biological activity by combining 
substitutions in the IL-6.~l site with Ala substitutions of 
2.2. Construction fexpression vectors single residues in the putative 5th helical region of 1L-6 
The T7 promoter vector pRSET6D was used for expression of IL-6 Expression vectors encoding IL-6.[~I/LR substitution mu- 
mutant proteins [14]. Construction of pRSET6D-IL-6.Q160E/T163P/ 
tant proteins combined with either E52A, $53A, $54A, F171L/S177R (IL-6.1]JLR) and pRSET6D-IL-6 mutant vectors with 
Ala substitutions of IL-6 residues E52, $53, $54, K55, E56, L58, and K55A, E56A, L58A or E60A were constructed and the pro- 
E60 has been described [14,17]. The Ala substitution mutants were reins were expressed in E. coli. Following partial purification 
combined with the I~I/LR substitutions by ligating Ncol-XbaI IL-6 of the IL-6 mutant  proteins, their capacity to stimulate the 
cDNA fragments from the Ala substitution plasmids into NcoI-Xbal proliferation of human XG- I  myeloma cells was tested. In 
digested pRSET6D-IL-6.[3flLR. Presence of the mutations was veri- 
combinat ion with the 131/LR substitutions, the L58A substitu- fled by restriction enzyme digestion [17] and/or nucleotide sequence 
analysis on dsDNA with the dideoxy chain termination method using tion resulted in a complete loss of activity. Also for the corn- 
the Sequenase kit (Biochemical Corporation, Cleveland, OH, USA). bination of IL-6.I~I/LR with either E52A, $53A, $54A, K55A, 
or E56A a significant loss of activity was observed (Fig. 1, 
2.3. Expression, purification and quantification fIL-6 mutant proteins Table 1). This reduction in activity was characterized both by 
For expression of the IL-6 mutant proteins the pRSET6D vectors 
were transformed to E.coli JM109 (DE3) (Promega) and the proteins an increase in EC50 value of the mutants and by a reduction 
were purified to ~ 80% homogeneity from inclusion bodies and quan- in the maximum induced response (Table 1). The maximum 
tified by radioimmunoassay as described [13]. response induced by the IL-6.S54A/131/LR mutant  was consis- 
2.4. IL-6 bioassays tently lower than that induced by the IL-6.E52A/[3flLR, IL- 
The human XG-1 myeloma nd TF-1 erythroleukemia proliferation 6.S53A/[3flLR, IL-6.K55AJ151/LR, and IL-6.E56A/[31/LR mu- 
assays were performed as described [14,15]. XG-1 cells were kindly tant proteins, which displayed similar residual activity. Similar 
provided by Dr. B. Klein (Institute for Molecular Genetics, CNRS, results were found when the capacity of the mutant  proteins 
Montpellier, France [18]). TF-1 cells were kindly provided by Dr. R. was measured to inhibit the proliferation of the human mel- 
Kastelein (DNAX, Palo Alto CA, USA). anoma cell line A375 (data not shown). To explain the ob- 
2.5. Receptor binding assay served reduction in biological activity of the mutant  proteins, 
To investigate the binding of IL-6 mutant proteins to IL-6Ra an receptor binding characteristics and reactivity with IL-6 con- 
ELISA was used in which the capacity of the IL-6 mutant proteins formation specific mAbs were determined. Compared to IL- 
Table 1 
Characteristics of IL-6.AIa substitution/[3flLR mutant proteins a 
XG-1 b shlL-6Ra c mAb binding (%)d 
Activity (%) Max. (%) binding (%) 8 12 14 
wtlL-6 100 100 100 100 100 100 
[~I/LR 1.18 + 0.36 86 + 26 17 + 4 70 + 10 50 + 22 74 + 14 
E52A/I31/LR 0.14 + 0.11 46 + 13 9 + 4 40 + 3 44 + 8 68 + 0.5 
S53A/[3flLR 0.21 + 0.06 55 + 16 14 + 6 39 + 0.5 36 + 13 65 + 5 
S54A/[~1/LR 0.09 + 0.06 24 + 6 17 + 8 28 + 4 31 _+ 11 47 + 12 
K55A/I31/LR 0.50 + 0.32 38 + 7 12 + 2 49 + 6 38 + 16 54 + 16 
E56A/I]l/LR 0.16 + 0.12 42 + 4 13 +_ 5 40 + 3 31 + 17 45 + 5 
L58A/~flLR < 0.0002 nd e 13 + 6 48 + 2 43 + 26 50 + 12 
E60A/I3flLR 0.84 + 0.46 68 + 19 21 + 7 45 + 2 60 + 11 55 + 5 
aData represent (ECs0 wtlL-6/ECs0 IL-6 mutant protein)× 100% (mean+ S.E.) for XG-1 and mAb binding experiments (ECs0, the effective 
concentration giving a half maximal response). For the shlL6Ra assay, data represent (IC~0 wtlL-6/ICs0 IL-6 mutant protein)× 100% (mean + S.E.; 
ICs0, concentration leading to half maximal competition). 
bData are derived from 3 independent experiments. ECs0 wtlL-6:19 + 2 pg/ml. Max. indicates the maximum proliferation induced by a mutant 
protein expressed as a percentage of the maximum of wtlL-6. 
Cn = 2; ECs0 wtlL-6:43 _+ 13 ng/ml. 
d n = 2 for mAb 8 and 14 ELI SAs, n = 3 for mAb 12 ELI SA. ECs0 wtlL-6 mAb 8, 0.9 + 0.3 ng/ml; mAb 12, 0.9 + 0.3 ng/ml; mAb 14, 0.7 + 0.1 ng/ml. 
eThe maximum induced response of the L58A/131/LR protein was < 5% of that of wtlL-6, which is within the S.E. of the background proliferation. 
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Fig. 1. Capacity of IL-6 Ala substitution/[31/LR mutant proteins to induce proliferation of XG-1 myeloma cells. XG-1 cells were cultured for 
3 days in the presence of the indicated concentrations of the IL-6 mutant proteins and the induced proliferation was measured by incorporation 
of tritiated thymidine. Background proliferation (mean + S.E.), 2.5 + 0.6 x 103 cpm. Data points represent the mean of triplicate measurements. 
One representative experiment out of three is shown. 
6.I]I/LR all mutant proteins retained a similar capacity to tion defects by occupancy of spare receptors has also been 
bind to sIL-6Ra (Table 1). The observed ifferences in bioac- described for mouse IL-2 mutant proteins [21]. 
tivity cannot be explained therefore by variability in IL-6Rc~ As is clear from Fig. 1, Table 1, and ref. [17], combining the 
binding. Also, the reactivity of the mutant proteins with IL-6 single Ala substitutions with the [31/LR substitutions resulted 
conformation specific mAbs that recognize different epitopes in a synergistic, rather than an additive loss of IL-6 bioactiv- 
on IL-6 was similar to that of IL-6.[31/LR (Table 1), suggest- ity. How can this synergism between the single Ala substitu- 
ing that compared to IL-6.131/LR gross structural perturba- tions and [3a-(Q160E/T163P) substitutions be explained at the 
tions do not occur in the combination mutants. Paonessa et structural level? (The 'LR' substitutions are not considered 
al. and Ciaponni et al. recently demonstrated that IL-6.131-site here because they do not play a role in gpl30 dimerization, 
mutant proteins (IL-6.T163D, or IL-6.W158R/D161R), but but affect IL-6R~ chain binding ([14] and references therein).) 
also IL-6.132 and IL-6.~1,2 combination mutant proteins, re- According to Wells, synergism between mutations in a protein 
tained the capacity to bind to sIL-6Rc~ and a single sgpl30 is observed when the mutated residues interact with each 
molecule [4,12]. This binding was proposed to occur through other, by direct contact or indirectly through electrostatic in- 
the I~a-region which is still intact in these mutant proteins teraction or structural perturbations, o that they no longer 
[4,12]. All these mutant proteins were impaired in their capac- behave independently [22]. Alternatively the mutation causes a 
ity to induce dimerization of sgp130 [4]. The same phenotype change in mechanism or rate-limiting step of the reaction [22]. 
was recently confirmed for the IL-6.[31 mutant protein Q160E/ We favor the first possibility to explain the observed synergy 
T163P used in this study, by Hammacher et al. [20]. Taken of the mutations in IL-6. In the 3D model of IL-6 Q160 is a 
together, these observations and our results suggest hat the surface exposed residue (Fig. 2). Substitution with Glu may 
reduced biological activity of the IL-6.131/LR Ala substitution therefore disturb a contact in the hexameric omplex. The 
mutants described here, as compared to that of the IL-6.~1/ contribution of Q160 to gpl30 dimerization likely is a small 
LR protein itself, is most likely due to a further decreased one based on the following considerations: the T163P substi- 
capacity to induce gpl30 dimerization. The dose-response tution alone results in a 250-fold reduced bioactivity on XG-1 
curves of wtIL-6 and the IL-6 mutant proteins in the XG-1 cells. Combination of T163P with Q160E further results in a 
assay suggest hat the defects in gpl30 dimerization capacity minor four-fold reduction in bioactivity [15]. Also, no loss of 
of the mutant proteins can be completely (IL-6.~a/LR) or bioactivity was detected by simultaneous Ala substitution of 
partially (IL-6.E52A/I]1/LR, IL-6.S53A/I]I/LR, IL-6.S54A/~l/ Q160 and D161 [15]. In contrast o the minor effects of Q160 
LR, IL-6.E56A/[3JLR) compensated for by the occupancy of substitutions, T163 substitutions can have large effects [15]. 
spare receptors: the ECs0 of the IL-6.1]I/LR protein is T163 is buried in the structure however, suggesting that the 
strongly increased, but there is no or little reduction in max- substitutions indirectly affect (a) surface exposed residue(s) 
imum response (Fig. 1, Table 1). For the above mentioned IL- (Fig. 2). In the model, the distances from the ~- and y-carbon 
6.~JLR Ala substitution mutants the increase in ECs0 is lar- of T163 to the r-carbon of A59 in the putative 5th helix are 
ger than the decrease in maximal response (Fig. 1, Table 1). 4.8 and 3.6 A respectively. Taking the hydrogen atoms into 
Such a partial or complete compensation for receptor activa- account, this suggests that these residues are in contact. Re- 
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Fig. 2. Location of T163 and residues in the 5th helical region in the tertiary structure model of hlL-6. Capitals indicate the positions of helices 
A-D. T163 is shown in blue spheres to emphasize close proximity to A59 (white); Q160 in blue sticks. L58 and $54 in the 5th helical region 
are shown in sticks. Color coding of the residues in the 5th helical region corresponds to their importance for IL-6 biological activity (ECs0 
values IL-6.Ala substitution/~3flLR mutant proteins in XG-1 assay (Table I): L58 in dark red). The position of the 'LR' (F171L and S177R) 
substitutions, affecting IL6Rc~ binding, is also indicated. 
placement of T163 with Pro could therefore induce a change $54 and L58 also contributes to the full gpl30 dimerization 
in the position of A59 and surrounding residues including the capacity of IL-6. Thus, together with replacement of in par- 
surface exposed L58. Apparently this conformational change ticular the L58 side chain, the conformational change induced 
is subtle and local, because we do not detect large changes in by T163P is sufficient to destroy the capacity of this region to 
binding affinity for sIL-6Ra and conformation specific mAb induce gpl30 dimerization. 
in binding experiments with a T163P (or Q160E/T163P) mu- 
tant protein [15]. As suggested by the residual bioactivity of 3.2. IL-6.L58Al~flLR is a specific IL-6 antagonist 
T163P and Q160E/T163P mutant proteins, this conforma- Because no biological activity of the IL-6.L58A/I3flLR mu- 
tional change is not sufficient o completely abolish gpl30 tant protein could be detected, we next determined whether it 
dimerization [13-15]. Apparently the presence of the side- could antagonize the activity of wtIL-6 on XG-1 cells. Addi- 
chains of residues E52, $53, K55, E56 and more importantly tion of 10 ~tg/ml of the IL-6.L58A/[31/LR mutant protein to 
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increasing concentrations of wtlL-6 reversibly inhibited the 6 
biological activity of wtlL-6 on XG-1 cells (Fig. 3A). Specifi- ~ 
2 5 
city of inhibition by the IL-6.L58A/~1/LR mutant protein was × 
further suggested by the observation that this protein specifi- ~ 4 
cally inhibited wtlL-6 activity, but not that of hOM, or hGM- 
CSF on the human erythroleukemia cell line TF-1 (Fig. 3B). "-~ 3 '4"LSSA/131/LRWtlL6 ( 00 pg/ml)+: 
We have previously shown that an IL-6.~I,e/LR mutant pro- ~ -~-'81,2/LR 
2 
XG- 1 , no  .6  
10- ¢,¢) 
"~ i i E 
t'-- ~ 0 I O0 1,000 I 0,000 
~ inhibitor eonc. (ng/ml) ¢d~ 8- 
O Fig. 4. IL-6.L58A/I~l/LR has a similar capacity to antagonize wtIL- 
¢" 6 activity as IL-6.131,2/LR. XG-1 cells were cultured with 100 pg/ml 
v 6- of wtlL-6 in the presence of increasing concentrations of IL- 
6.L58A/I~flLR or IL-6.I3],2/LR. Proliferation (mean+ S.E.) induced 
by 100 pg/ml wtIL-6, 5.0+0.4× 103 cpm; background proliferation 
¢'~ 1.1 × 10 a cpm. The mean of triplicate measurements of one experi- 
O 4- ment out of two is shown. 
6 
.F_ 
~, 2- tein could antagonize wtIL-6 activity on XG-1 cells [14]. In + L58A/B1/LR 
¢" (10 /~g/ml) this protein K42-A57 of human IL-6 had been replaced with 
the corresponding mouse residues, resulting in 10 amino acid 
"1" [] . . . . .  substitutions, in addition to the 4 ~I/LR substitutions. When 
O 1 10 100 1,000 10,0001OO,000 we compared the antagonistic apacity of the IL-6.L58A/~1/ 
wi lL6  (ng/m[) LR mutant protein with that of IL-6.131,2/LR, both proteins 
were found equally potent in inhibiting wtIL-6 activity on 
XG-1 cells (Fig. 4). 
In conclusion we have shown that besides L58, residue $54, 
TF -R  and to a lesser extent residues E52, $53, K55 and E56 in the 
140 putative 5th helical region in the A-B  loop of IL-6 are im- 
"~'~ ~ + hGM-CSF  ~lb portant for bioactivity of IL-6. These residues likely contrib- 
120 ute to the IL-6Rc~-chain-dependent dimerization of the IL-6 
signal transducer gpl30. In addition we have shown that a 
O 1001 mutant protein with only five substitutions (IL-6.L58A/[~fl 
LR) has a similar capacity to antagonize wtlL-6 as the pre- 
80 viously described IL-6.131,2/LR mutant protein, in which 14 
residues of hlL-6 were replaced. When considering therapeu- 
._ so tical application of IL-6 receptor antagonists, minimization of 
the number of amino acid substitutions in these molecules, 
40 may reduce their potential immunogenicity. 
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